A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma
Clinical trial NCT05309421 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05309421
- Sponsor
- Evaxion Biotech A/S
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-09-19
- Primary completion
- 2025-09-30
- Enrollment
- 17
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.